[Federal Register Volume 67, Number 2 (Thursday, January 3, 2002)]
[Notices]
[Page 350]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-98]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Origen Therapeutics, Inc./Embrex, Inc.

    Notice is hereby given that, on October 23, 2001, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Origen Therapeutics, Inc./
Embrex, Inc. has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing (1) the 
identifies of the parties and (2) the nature and objectives of the 
venture. The notifications were filed for the purpose of invoking the 
Act's provisions limiting the recovery of antitrust plaintiffs to 
actual damages under specified circumstances. Pursuant to section 6(b) 
of the Act, the identifies of the parties are Origen Therapeutics, 
Inc., Burlingame, CA; and Embrex, Inc., Research Triangle Park, NC. The 
nature and objectives of the venture are to conduct research on the use 
of avian embryonic stem cell technology, coupled with automated egg 
injection technology to form highly chimeric poultry. The activities of 
this joint venture will be partially funded by an award from the 
Advanced Technology Program, National Institute of Standards and 
Technology, Department of Commerce.

Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 02-98 Filed 1-2-02; 8:45 am]
BILLING CODE 4410-11-M